China Deal-Making Now: New Opportunities and Barriers
4:00 PM - 5:00 PM (PDT), Tuesday, October 13, 2020
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Deloitte reports a cooling down effect in biopharma cross-border transactions in 2019 due political and trade tensions. When comparing against recent years, deal counts have decreased and deal values are remaining flat, with over 83% of deals under $100m. While the current pandemic has also added to this trend, further disrupting partnership opportunities with Chinese companies, it has also prompted other forms of biopharma collaborations. Join China deal-making experts from pharma, biotech and venture as they discuss what factors are being considered in evaluating current partnership opportunities.